A randomized, double-blind, placebo-controlled, 5-arm parallel study to evaluate the pharmacokinetics/pharmacodynamics and steady state efficacy of once or twice daily bilastine (10 or 20 mg) compared with placebo given orally in the treatment of the symptoms of seasonal allergic rhinitis in an environmental exposure chamber (EEC) mode

Trial Profile

A randomized, double-blind, placebo-controlled, 5-arm parallel study to evaluate the pharmacokinetics/pharmacodynamics and steady state efficacy of once or twice daily bilastine (10 or 20 mg) compared with placebo given orally in the treatment of the symptoms of seasonal allergic rhinitis in an environmental exposure chamber (EEC) mode

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2009

At a glance

  • Drugs Bilastine (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jan 2009 Planned number of patients changed from 500 to 502 as reported by ClinicalTrials.gov.
    • 09 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top